6 completed, 1 active not recruiting, 1 recruiting. 8 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 8 | Completed 6, Active not recruiting 1, Recruiting 1 |
Follow vilanterol: new trials by email Literature Review of vilanterol trials Research Report on vilanterol
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| VENTURI (VENTilation Using Respiratory Imaging) Beclomethasone Dipropionate/Formoterol Fumarate/Glycopyrrolate pMDI, Fluticasone Furoate/Umeclidinium/Vilanterol 100 MCG/1 ACTUATION-62.5 MCG/1 ACTUATION-25 MCG/1 ACTUATION Inhalation Powder - Asthma | Phase 2 | Recruiting | University of Alabama at Birmingham | 20 | 2026-03-15 | 2026-04-13 |
| A Single Inhalation Dose Study to Assess Efficacy, Pharmacokinetics (PK), Safety and Tolerability of AZD8871 in Patients With Long-term Lung Diseases. AZD8871, Anoro® Ellipta® - Chronic Obstructive Pulmonary Disease | Phase 2 | Completed | AstraZeneca | 73 | 2018-10-10 | 2020-12-17 |
| Hyperpolarized Xenon-129 MRI: a New Multi-dimensional Biomarker to Determine Pulmonary Physiologic Responses to COPD Therapeutics Anoro Ellipta, Arnuity Ellipta - Chronic Obstructive Pulmonary Disease | Phase 2 | Active not recruiting | University of Virginia | 95 | 2017-11-05 | 2024-11-18 |
| A Phase IIA FF/VI Study to Measure FeNO in Asthmatic Patients. Fluticasone furoate (FF) (100 mcg), Vilanterol (VI) (25 mcg), Placebo - Asthma | Phase 2 | Completed | GlaxoSmithKline | 28 | 2016-04-29 | 2018-08-28 |
| Dose-Finding Study of Batefenterol (GSK961081) Via Dry Powder Inhaler in Patients With Chronic Obstructive Pulmonary Disease (COPD) Batefenterol, Umeclidinium/ Vilanterol, Placebo - Pulmonary Disease, Chronic Obstructive | Phase 2 | Completed | GlaxoSmithKline | 325 | 2015-11-06 | 2019-07-16 |
| Dose-ranging Study of Vilanterol (VI) Inhalation Powder in Children Fluticasone propionate 100mcg, Placebo, Vilanterol - Asthma | Phase 2 | Completed | GlaxoSmithKline | 463 | 2012-04-01 | 2017-01-09 |
| Inhaled Fluticasone Furoate/Vilanterol Safety and Tolerability, PK and PD Study Fluticasone Furoate, Fluticasone Furoate/Vilanterol - Asthma | Phase 2 | Completed | GlaxoSmithKline | 26 | 2011-10-01 | 2017-01-11 |
| A Study in Asthmatic Patients to Determine if There is Any Difference in Dosing With Fluticasone Furoate/Vilanterol Inhalation Powder in the Morning or Evening on Lung Function FF(100mcg)/Vilanterol(25mcg) AM, FF(100mcg)/Vilanterol(25mcg) PM, Placebo AM - Asthma | Phase 2 | Completed | GlaxoSmithKline | 26 | 2010-10-01 | 2017-01-11 |
Asthma (5) · Pulmonary Disease, Chronic Obstructive (3) · Emphysema (2)
GlaxoSmithKline (5) · AstraZeneca (1) · University of Alabama at Birmingham (1) · University of Virginia (1)
United States (5) · Germany (3) · New Zealand (2) · South Africa (2) · Argentina (1) · Chile (1) · Georgia (1) · Japan (1) · Mexico (1) · Peru (1) · Philippines (1) · Poland (1) · Puerto Rico (1) · Slovakia (1) · Ukraine (1)
Kun Qing, PhD (1) · Yun M Shim, MD (1)
PMID 23681559, PMID 24200619, PMID 25146558, PMID 27044326, PMID 30001712, PMID 34503985, PMID 36127726
2015 (1)